Affiliation:
1. Memorial Healthcare System, Pembroke Pines, FL 33021, USA
2. Moffitt Malignant Hematology at Memorial Healthcare System, Pembroke Pines, FL 33021, USA
Abstract
Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized the landscape for the treatment of hematological malignancies, solid tumors, and, recently, autoimmune disorders. The BTK receptor is expressed in several hematopoietic cells such as macrophages, neutrophils, mast cells, and osteoclasts. Similarly, the BTK receptor is involved in signaling pathways such as chemokine receptor signaling, Toll-like receptor signaling, and Fc receptor signaling. Due to their unique mechanism, these agents provide a diverse utility in a variety of disease states not limited to the field of malignant hematology and are generally well-tolerated.
Reference60 articles.
1. Tasso, B., Spallarossa, A., Russo, E., and Brullo, C. (2021). The Development of BTK Inhibitors: A Five-Year Update. Molecules, 26.
2. Targeting B cell receptor signalling in cancer: Preclinical and clinical advances;Burger;Nat. Rev. Cancer,2018
3. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: Mechanisms and clinical studies;Alu;J. Hematol. Oncol.,2022
4. Bruton Tyrosine Kinase Inhibitors: Present and Future;Burger;Cancer J.,2019
5. Tec family of protein-tyrosine kinases: An overview of their structure and function;Mano;Cytokine Growth Factor Rev.,1999
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献